MP Group: Outlook on the mRNA Bio-CDMOs – A key catalyst for the evolution of mRNA therapeutics
It is our pleasure to share with you our outlook on the ‘mRNA Bio-CDMOs – A key catalyst for the evolution of mRNA therapeutics.’ mRNA therapeutics played a pivotal role in the pandemic management thereby generating unparalleled interests (and investments) across the biopharma as well as investor groups. mRNA Covid-19 vaccines have paved the pathway for regulatory approvals. As a result, the clinical pipeline of mRNA therapeutics has expanded several fold across wide range of indications beyond infectious disease such…